Researchers at Houston Methodist Research Institute developed a tiny drug delivery device for addressing difficult-to-treat cancers.
The researchers published their work in a paper in Advanced Science. They used an implantable nanofluidic device they invented to deliver CD40 monoclonal antibodies (mAB). The team calls the device a nanofluidic drug-eluting seed (NDES).
With the device — smaller than a grain of rice — they delivered immunotherapy directly into the tumor at a sustained low dose. This investigation took place in murine (rodent) models.
Researchers observed tumor reduction at a four-fold lower dosage compared to traditional systemic immunotherapy treatment.
Get the full story at our sister site, Drug Delivery Business News.